疫苗行业事件点评：国内企业积极布局RSV疫苗，首款RSV mRNA疫苗获批临床

Investment Rating - The industry investment rating is "Overweight" [1] Core Insights - The first domestic RSV mRNA vaccine has been approved for clinical trials, marking a significant milestone in the industry [2][4] - Vaccination against RSV is crucial for preventing severe infections and reducing mortality, especially among high-risk groups such as infants, the elderly, and immunocompromised individuals [3] - The lack of effective drugs and increased awareness of RSV diagnosis and treatment are driving the rapid development of RSV vaccines [5] - The industry is expected to experience long-term growth driven by policy support, increasing demand, and technological innovation [6][7] Summary by Sections Industry Performance - The industry has shown relative returns of -10% over one month, -26% over three months, and -28% over twelve months compared to the CSI 300 index [1] Recent Developments - The first domestic RSV mRNA vaccine, IN006, developed by Deep Trust Bio, has received clinical trial approval from the National Medical Products Administration (NMPA) [2][4] - Currently, there are three RSV vaccines available globally, with domestic companies actively pursuing RSV vaccine development [4] Market Dynamics - The global RSV vaccine market is anticipated to grow rapidly as new vaccines with better preventive effects are introduced [5] - The demand for vaccines is expected to increase due to rising vaccination willingness and an aging population [7] Investment Strategy - The report suggests focusing on technological innovation and the launch of significant products, as these will be key to the industry's long-term success [6][7]